Maxwell Biomedical

Executive Summary

Maxwell Biomedical is a privately held, pre-clinical stage medical device company based in San Francisco, developing Maxwell Rhythm360, a breakthrough therapy for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF). The company’s Sinus Rhythm Therapy (SRT) is a non-destructive approach that uses advanced inter-cardiac monitoring to detect AF triggers and deliver preemptive therapy, aiming to restore functional sinus rhythm and optimize atrial function. This novel mechanism could address a significant unmet need, as AF and HFpEF frequently co-exist and current treatments are often inadequate. The technology has the potential to reduce AF burden and improve clinical outcomes without the collateral damage associated with traditional ablation. As a pre-clinical entity, Maxwell Biomedical has not yet reported any clinical data or generated revenue. The company likely relies on venture capital funding and may be seeking Series A financing to advance its technology toward first-in-human studies. The main risks include early-stage regulatory hurdles, potential technical challenges in demonstrating safety and efficacy, and competition from established ablation therapies. Success depends on validating the SRT platform in vivo and securing sufficient capital for clinical development. If successful, Maxwell Rhythm360 could become a differentiated option for the large, underserved AF-HFpEF population.

Upcoming Catalysts (preview)

• Q2 2026Completion of Preclinical Proof-of-Concept Study60% success
• Q3 2026Series A Funding Round70% success
• Q4 2026FDA Pre-Submission Meeting or Investigational Device Exemption Filing50% success